IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway [Yahoo! Finance]
Clene Inc. (CLNN)
Company Research
Source: Yahoo! Finance
The FDA recommended using neurofilament light chain biomarker analyses to substantiate the drug's efficacy. Clene is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. Clinical findings presented at an FDA meeting highlighted CNM-Au8's significant survival benefits and benign safety profile, underscoring its potential as a transformative ALS therapy. The press release is to inform the public about Clene's progress with CNM-Au8 and its interactions with the FDA. IBN (InvestorBrandNetwork) is a communications and digital engagement platform that provides tailored Platform Solutions for select private and public companies, and is responsible for dissemina
Show less
Read more
Impact Snapshot
Event Time:
CLNN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLNN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLNN alerts
High impacting Clene Inc. news events
Weekly update
A roundup of the hottest topics
CLNN
News
- Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $23.00 price target on the stock.MarketBeat
- Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan [Yahoo! Finance]Yahoo! Finance
- Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior LoanGlobeNewswire
- Clene Inc. (NASDAQ: CLNN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $23.00 price target on the stock.MarketBeat
- FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS [Yahoo! Finance]Yahoo! Finance
CLNN
Earnings
- 11/13/24 - Beat
CLNN
Sec Filings
- 12/20/24 - Form 8-K
- 12/10/24 - Form 424B5
- 12/10/24 - Form 8-K
- CLNN's page on the SEC website